Predictive and prognostic biomarkers can be an attractive strategy for stratifying patients who are likely to benefit from treatment. Our noninvasive biomarkers can do just that and much more. In addition, we have a novel serum biomarker for calprotectin that is extremely popular for clinical programs in inflammatory bowel diseases such as Ulcerative Colitis and Crohn's Disease.
More about our biomarkers for IBD
Nordic Bioscience effectively integrates innovative translational models with ProteinFingerPrint Technology™ to translate findings efficiently. By using the same biomarkers throughout various clinical development stages, they create a seamless link between preclinical models and clinical applications. This strategically chosen development pathway significantly boosts the efficiency of drug development pipelines.
More about translational models in IBD
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
